itacitinib + ibrutinib

Itacitinib + ibrutinib is an investigational combination of two oral small molecule inhibitors: itacitinib, a selective Janus kinase 1 (JAK1) inhibitor, and ibrutinib, an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and interleukin-2–inducible kinase (ITK)[2][4][5][6]. - **Itacitinib** selectively inhibits JAK1, reducing signaling through pathways such as the JAK-STAT cascade, important in inflammation and growth of certain cancers, supporting anti-proliferative and anti-inflammatory effects[5]. - **Ibrutinib** covalently inhibits BTK, a key mediator of B-cell receptor signaling, preventing B-cell growth and survival; it also irreversibly inhibits ITK, modulating T-helper cell activity, and impacts downstream pathways including PLC-γ, ERK1/2, PI3K, and NF-κB[2][4][6]. This combination aims to provide enhanced anti-cancer efficacy by dual targeting of B-cell and inflammatory pathways, relying on synergistic suppression of malignant cell growth and immune modulation. Both drugs are orally administered and developed for various hematologic and solid tumors.

Other names

itacitinib + ibrutinib